The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
miR-200a Regulates Nrf2 Activation by Targeting Keap1 mRNA in Breast Cancer Cells
Open accessAbstract
NF-E2-related factor 2 (Nrf2) is an important transcription factor that activates the expression of cellular detoxifying enzymes. Nrf2 expression is largely regulated through the association of Nrf2 with Kelch-like ECH-associated protein 1 (Keap1), which results in cytoplasmic Nrf2 degradation. Conversely, little is known concerning the regulation of Keap1 expression. Until now, a regulatory role for microRNAs (miRs) in controlling Keap1 gene expression had not been characterized. By using miR array-based screening, we observed miR-200a silencing in breast cancer cells and demonstrated that upon re-expression, miR-200a targets the Keap1 3'-untranslated region (3'-UTR), leading to Keap1 mRNA degradation. Loss of this regulatory mechanism may contribute to the dysregulation of Nrf2 activity in breast cancer. Previously, we have identified epigenetic repression of miR-200a in breast cancer cells. Here, we find that treatment with epigenetic therapy, the histone deacetylase inhibitor suberoylanilide hydroxamic acid, restored miR-200a expression and reduced Keap1 levels. This reduction in Keap1 levels corresponded with Nrf2 nuclear translocation and activation of Nrf2-dependent NAD(P)H-quinone oxidoreductase 1 (NQO1) gene transcription. Moreover, we found that Nrf2 activation inhibited the anchorage-independent growth of breast cancer cells. Finally, our in vitro observations were confirmed in a model of carcinogen-induced mammary hyperplasia in vivo. In conclusion, our study demonstrates that miR-200a regulates the Keap1/Nrf2 pathway in mammary epithelium, and we find that epigenetic therapy can restore miR-200a regulation of Keap1 expression, therefore reactivating the Nrf2-dependent antioxidant pathway in breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2008) · doi:10.1038/nrg2290 · Cited by 5,199
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,863
Many roads to maturity: microRNA biogenesis pathways and their regulation
Winter, J., Jung, S., Keller, S., Gregory, R. I., & Diederichs, S. (2009) · Nature Cell Biology · doi:10.1038/ncb0309-228 · Cited by 2,656
Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398899 · Cited by 1,947
Nrf2:INrf2 (Keap1) signaling in oxidative stress
Kaspar, J. W., Niture, S. K., & Jaiswal, A. K. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.07.035 · Cited by 1,648
Ramos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060
Bracken, C. P., Gregory, P. A., Kolesnikoff, N., Bert, A. G., Wang, J., Shannon, M. F., & Goodall, G. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1942 · Cited by 1,060
Wakabayashi, N., Dinkova-Kostova, A. T., Holtzclaw, W. D., Kang, M.-I., Kobayashi, A., Yamamoto, M., Kensler, T. W., & Talalay, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307301101 · Cited by 986
Kobayashi, M., & Yamamoto, M. (2006) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2006.01.007 · Cited by 856
Furukawa, M., & Xiong, Y. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.1.162-171.2005 · Cited by 746
Redox Regulation in Cancer: A Double‐edged Sword with Therapeutic Potential
Acharya, A., Das, I., Chandhok, D., & Saha, T. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.1.10095 · Cited by 486
Nrf2: friend or foe for chemoprevention?
Kensler, T. W., & Wakabayashi, N. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp231 · Cited by 484
Epigenetic inactivation of microRNA gene hsa‐mir‐9‐1 in human breast cancer
Lehmann, U., Hasemeier, B., Christgen, M., Müller, M., Römermann, D., Länger, F., & Kreipe, H. (2008) · The Journal of Pathology · doi:10.1002/path.2251 · Cited by 460
Epigenetic regulation of microRNA expression in colorectal cancer
Bandres, E., Agirre, X., Bitarte, N., Ramirez, N., Zarate, R., Roman‐Gomez, J., Prosper, F., & Garcia‐Foncillas, J. (2009) · International Journal of Cancer · doi:10.1002/ijc.24638 · Cited by 439
MicroRNAs and their target gene networks in breast cancer
O'Day, E., & Lal, A. (2010) · Breast Cancer Research · doi:10.1186/bcr2484 · Cited by 439
Nrf2 signaling and cell survival
Niture, S. K., Kaspar, J. W., Shen, J., & Jaiswal, A. K. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.06.009 · Cited by 398
Zhang, P., Singh, A., Yegnasubramanian, S., Esopi, D., Kombairaju, P., Bodas, M., Wu, H., Bova, S. G., & Biswal, S. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0589 · Cited by 374
Iida, K., Itoh, K., Kumagai, Y., Oyasu, R., Hattori, K., Kawai, K., Shimazui, T., Akaza, H., & Yamamoto, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1906 · Cited by 370
Nrf1 and Nrf2 Play Distinct Roles in Activation of Antioxidant Response Element-dependent Genes
Ohtsuji, M., Katsuoka, F., Kobayashi, A., Aburatani, H., Hayes, J. D., & Yamamoto, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804597200 · Cited by 317
Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer
Khor, T. O., Huang, M.-T., Prawan, A., Liu, Y., Hao, X., Yu, S., Cheung, W. K. L., Chan, J. Y., Reddy, B. S., Yang, C. S., et al. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0028 · Cited by 306
Vrba, L., Jensen, T. J., Garbe, J. C., Heimark, R. L., Cress, A. E., Dickinson, S., Stampfer, M. R., & Futscher, B. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008697 · Cited by 285
MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism
Yang, M., Yao, Y., Eades, G., Zhang, Y., & Zhou, Q. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1604-1 · Cited by 280
Self-citationTellez, C. S., Juri, D. E., Do, K., Bernauer, A. M., Thomas, C. L., Damiani, L. A., Tessema, M., Leng, S., & Belinsky, S. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3035 · Cited by 277
Clinical Trials with Oncolytic Adenovirus in China
Yu, W., & Fang, H. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907780058817 · Cited by 274
de Souza Rocha Simonini, P., Breiling, A., Gupta, N., Malekpour, M., Youns, M., Omranipour, R., Malekpour, F., Volinia, S., Croce, C. M., Najmabadi, H., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1318 · Cited by 267
Eades, G., Yao, Y., Yang, M., Zhang, Y., Chumsri, S., & Zhou, Q. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229401 · Cited by 263
Self-citationNrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy
Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., Copple, I. M., Williams, S., Owen, A., Neoptolemos, J. P., et al. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-37 · Cited by 242
Potential Mechanisms of Estrogen Quinone Carcinogenesis
Bolton, J. L., & Thatcher, G. R. J. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700191p · Cited by 241
Ahmad, A., Aboukameel, A., Kong, D., Wang, Z., Sethi, S., Chen, W., Sarkar, F. H., & Raz, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0965 · Cited by 205
Uhlmann, S., Zhang, J. D., Schwäger, A., Mannsperger, H., Riazalhosseini, Y., Burmester, S., Ward, A., Korf, U., Wiemann, S., & Sahin, Ö. (2010) · Oncogene · doi:10.1038/onc.2010.201 · Cited by 199
The Quest for the 1p36 Tumor Suppressor
Bagchi, A., & Mills, A. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2095 · Cited by 196
Regulation of Late G1/S Phase Transition and APCCdh1by Reactive Oxygen Species
Havens, C. G., Ho, A., Yoshioka, N., & Dowdy, S. F. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00303-06 · Cited by 180
MicroRNAs, cancer and cancer stem cells
Zimmerman, A. L., & Wu, S. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.09.019 · Cited by 173
Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling.
Sarkar, S., Abujamra, A. L., Loew, J. E., Forman, L. W., Perrine, S. P., & Faller, D. V. (2011) · PubMed · Cited by 143
Santini, V., Gozzini, A., & Ferrari, G. (2007) · Current Drug Metabolism · doi:10.2174/138920007780655397 · Cited by 131
Kovalchuk, O., Tryndyak, V., Montgomery, B. A., Boyko, A., Kutanzi, K. R., Zemp, F. J., Warbritton, A. R., Latendresse, J. R., Kovalchuk, I., Beland, F. A., et al. (2007) · Cell Cycle · doi:10.4161/cc.6.16.4549 · Cited by 130
Epigenetic control of the expression of a primate-specific microRNA cluster in human cancer cells
Tsai, K., Kao, H.-W., Chen, H., Chen, S.-J., & Lin, W. (2009) · Epigenetics · doi:10.4161/epi.4.8.10230 · Cited by 116
Shin, D., Park, H.-M., Jung, K.-A., Choi, H.-G., Kim, J., Kim, D., Kim, S. G., Kang, K. W., Ku, S., Kensler, T. W., et al. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.01.021 · Cited by 114
Muscarella, L. A., Barbano, R., D’Angelo, V., Copetti, M., Coco, M., Balsamo, T., la Torre, A., Notarangelo, A., Troiano, M., Parisi, S., et al. (2011) · Epigenetics · doi:10.4161/epi.6.3.14408 · Cited by 108
Loignon, M., Miao, W., Hu, L., Bier, A., Bismar, T. A., Scrivens, P. J., Mann, K. K., Basik, M., Bouchard, A., Fiset, P., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1186 · Cited by 105
Increased cell migration and plasticity in Nrf2-deficient cancer cell lines
Rachakonda, G., Sekhar, K. R., Jowhar, D., Samson, P. C., Wikswo, J. P., Beauchamp, R. D., Datta, P. K., & Freeman, M. L. (2010) · Oncogene · doi:10.1038/onc.2010.118 · Cited by 101
Lee, S., Jung, J.-W., Park, S., Roh, K.-H., Lee, S. Y., Kim, J. H., Kang, S.-K., & Kang, K. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0457-9 · Cited by 101
Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling
Yao, Y., Li, H., Gu, Y., Davidson, N. E., & Zhou, Q. Y. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp308 · Cited by 92
Self-citationInhibition of estrogen signaling activates the NRF2 pathway in breast cancer
Yao, Y., Brodie, A. M. H., Davidson, N. E., Kensler, T. W., & Zhou, Q. Y. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1023-8 · Cited by 91
Self-citationMense, S. M., Remotti, F., Bhan, A., Singh, B. P., El-Tamer, M. B., Hei, T. K., & Bhat, H. K. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.06.007 · Cited by 87
Aoki, Y., Hashimoto, A. S., Amanuma, K., Matsumoto, M., Hiyoshi, K., Takano, H., Masumura, K., Itoh, K., Nohmi, T., & Yamamoto, M. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3355 · Cited by 84
Classifying microRNAs in cancer: The good, the bad and the ugly
Voorhoeve, P. M., & Agami, R. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.11.003 · Cited by 72
Hsieh, T., Elangovan, S., & WU, J. M. (2010) · PubMed · Cited by 60
Targeting Carcinogen Metabolism by Dietary Cancer Preventive Compounds
Yu, S., & Kong, A. T. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907781386669 · Cited by 57
Zhou, H., Mazan-Mamczarz, K., Martindale, J. L., Barker, A. J., Liu, Z., Gorospe, M., Leedman, P. J., Gartenhaus, R. B., Hamburger, A. W., & Zhang, Y. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq084 · Cited by 42
Self-citation
Cited by
Loboda, A., Damulewicz, M., Pyza, E., Jozkowicz, A., & Dulak, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2223-0 · Cited by 2,632
Transcriptional Regulation by Nrf2
Tonelli, C., Chio, I. I. C., & Tuveson, D. A. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7342 · Cited by 2,192
The Nrf2 regulatory network provides an interface between redox and intermediary metabolism
Hayes, J. D., & Dinkova-Kostova, A. T. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.02.002 · Cited by 2,141
Ferroptosis, a new form of cell death: opportunities and challenges in cancer
Mou, Y., Wang, J., Wu, J., He, D., Zhang, C., Duan, C., & Li, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0720-y · Cited by 1,930
The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway
Baird, L., & Yamamoto, M. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00099-20 · Cited by 1,542
Metadata
- Authors
- Eades, G., Yang, M., Yao, Y., Zhang, Y., & Zhou, Q.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2011-11
- Volume
- 286
- Issue
- 47
- Pages
- 40725-40733
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2004840945
- Cited by
- 305
- References
- 52
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.